シンプトマティック・ハイパートロフィック・カルディオミオパシーにおけるミトラ・トランスキャセターのエッジ・トゥ・エッジ修復: 系統的レビュー
PubMedで要約を見る
まとめ
この要約は機械生成です。ミトラル・トランスキャセター・エッジ・トゥ・エッジ (M-TEER) の修復は,流出管阻害による高縮性心筋病 (HCM) の治療に有望である. この最小侵襲的処置は,他の治療法に適さない患者の障害を大幅に軽減し,症状を改善しました.
科学分野
- 心臓病科
- 介入心臓科
- 心臓外科
背景
- 左心室流出管 (LVOT) 阻害による多動性心筋病 (HCM) は,複雑な臨床的課題を提示する.
- 縮治療 (SRT) は主要な治療法ですが,回回転 (M-TEER) が回転 (MR) と回前動 (SAM) に関するLVOT阻害のために出現しています.
研究 の 目的
- 症状のあるHCM患者の治療におけるM- TEERの有効性と安全性を評価する.
主な方法
- コクラン・ハンドブックとPRISMAのガイドラインに従って,体系的なレビューが行われました.
- Embase,PubMed,ScopusでM-TEERで管理された症状性HCMの症例報告を検索しました.
- 抽出したデータには,患者の人口統計,手順の詳細,血液動力学,およびアウトカムが含まれています.
主要な成果
- 症状のあるHCMの20人の患者がM- TEERを受けた. 主に男性 (60%),平均年齢73. 06歳.
- M-TEERは,LVOTグラデント (68. 9から12. 35mmHg),MRグレード (2. 68),NYHAクラス (2) を大幅に改善しました.
- 19件の手術が成功し 1人の患者は心臓ショックで死亡しました
結論
- M-TEERは,特にSRTが不適切である場合,MRとSAMに二次的なLVOT阻害を有する症状性HCMの実行可能で安全な選択肢です.
- 長期の有効性と結果を確認するには,より大規模な研究が必要である.
関連する概念動画
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...

